Daily FNArena News - Australia

Transurban performed to expectations in its FY14 results and brokers expect the outlook will remain strong while interest rates are favourable.

Cochlear surprised the market and brokers with a better performance in the second half, but concerns abound around market share and growth in the company’s core business.

A summary of the previous session’s corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

A wrap of the day’s activity on the Australian stock market.

Will KKR pull its bid for Treasury Wine following due dilligence? Or could another bidder emerge?

While some brokers have brushed aside recent sales weakness as temporary, others are not so sure ResMed’s growth rates will rebound substantially.

A wrap of the day’s activity on the Australian stock market.

A summary of the previous session’s corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

Weekly update on recommendation, target price, and earnings forecast changes.

A wrap of the day’s activity on the Australian stock market.